Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)

Summary

This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with mild to moderate obstructive sleep apnea (OSA) compared to administration of placebo. The primary hypothesis of this study is that multiple doses of MK-4305 do not produce a clinically significant increase in Apnea-Hypopnea Index (AHI) in participants with mild to moderate OSA, as compared to placebo.

Timeline

Start

2011-03-19

Primary completion

2011-08-11

Completion

2011-08-11

Publications

• Results Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.

Drugs

Indications